Diabetes abrogates sex differences and aggravates cardiometabolic risk in postmenopausal women

[1]  G. Norata,et al.  High-Density Lipoprotein Subfractions - What the Clinicians Need to Know , 2013, Cardiology.

[2]  Sex-specific differences in long-term glycemic control and cardiometabolic parameters in patients with type 1 diabetes treated at a tertiary care centre , 2012, Wiener klinische Wochenschrift.

[3]  S. Stone-Elander,et al.  Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes , 2012, Nature.

[4]  M. G. Modena,et al.  [Is menopause a risk factor for ischemic heart disease in women?]. , 2012, Giornale italiano di cardiologia.

[5]  M. Fernandez,et al.  Inflammation and type 2 diabetes. , 2012, Diabetes & metabolism.

[6]  T. Miazgowski,et al.  Serum adiponectin, bone mineral density and bone turnover markers in post‐menopausal women with newly diagnosed Type 2 diabetes: a 12‐month follow‐up , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[7]  S. Ho,et al.  The association of serum C-reactive protein, uric acid and magnesium with insulin resistance in Chinese postmenopausal women with prediabetes or early untreated diabetes. , 2011, Maturitas.

[8]  R. Hu,et al.  Serum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetes , 2011, Cardiovascular diabetology.

[9]  K. Kohara,et al.  Association between fasting plasma glucose and high-sensitivity C-reactive protein: gender differences in a Japanese community-dwelling population , 2011, Cardiovascular diabetology.

[10]  S. Baumgartner-Parzer,et al.  Relations of adiponectin to levels of metabolic parameters and sexual hormones in elderly type 2 diabetic patients. , 2011, Gender medicine.

[11]  G. Moneta.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2011 .

[12]  R. Lemmens‐Gruber,et al.  Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus. , 2010, Gender medicine.

[13]  D. Fuchs,et al.  Inflammation, adiponectin, obesity and cardiovascular risk. , 2010, Current medicinal chemistry.

[14]  J. Boavida,et al.  First diabetes prevalence study in Portugal: PREVADIAB study , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[15]  J. Danesh,et al.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. , 2010, Lancet.

[16]  M. Kaushik,et al.  Cardiovascular disease and androgens: a review. , 2010, International journal of cardiology.

[17]  D. Cucinotta,et al.  Influence of menopause and cholesteryl ester transfer protein (CETP) TaqIB polymorphism on lipid profile and HDL subpopulations distribution in women with and without type 2 diabetes. , 2010, Atherosclerosis.

[18]  C. Fox.  Cardiovascular disease risk factors, type 2 diabetes mellitus, and the Framingham Heart Study. , 2010, Trends in cardiovascular medicine.

[19]  M. Fiuza,et al.  Prevalence, management and control of diabetes mellitus and associated risk factors in primary health care in Portugal. , 2010, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[20]  Shao-Sung Huang,et al.  Association of adiponectin with future cardiovascular events in patients after acute myocardial infarction. , 2010, Journal of atherosclerosis and thrombosis.

[21]  Rakesh K. Sharma,et al.  Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk , 2009, Vascular health and risk management.

[22]  J. Tuomilehto,et al.  The impact of dyslipidaemia on cardiovascular mortality in individuals without a prior history of diabetes in the DECODE Study. , 2009, Atherosclerosis.

[23]  Mats Eliasson,et al.  The impact of diabetes on coronary heart disease differs from that on ischaemic stroke with regard to the gender , 2009, Cardiovascular diabetology.

[24]  C. Lavie,et al.  The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. , 2008, Reviews in cardiovascular medicine.

[25]  V. Tikhonoff,et al.  Menopause does not affect blood pressure and risk profile, and menopausal women do not become similar to men , 2008, Journal of hypertension.

[26]  Giuseppe Lippi,et al.  High Serum Uric Acid as a Novel Risk Factor for Type 2 Diabetes , 2008, Diabetes Care.

[27]  M. Alevizaki,et al.  Severity of coronary artery disease in postmenopausal diabetic women , 2008, Hormones.

[28]  R. Hegele,et al.  Emerging antidyslipidemic drugs. , 2008, Expert opinion on emerging drugs.

[29]  J. Shepherd,et al.  Dyslipidaemia in diabetic patients: time for a rethink , 2007, Diabetes, obesity & metabolism.

[30]  J. Shaw,et al.  Risk of Cardiovascular and All-Cause Mortality in Individuals With Diabetes Mellitus, Impaired Fasting Glucose, and Impaired Glucose Tolerance: The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) , 2007, Circulation.

[31]  M. Goodarzi,et al.  Relationship of serum adiponectin with blood lipids, HbA1c, and hs‐CRP in type II diabetic postmenopausal women , 2007, Journal of clinical laboratory analysis.

[32]  A. Tenenbaum,et al.  Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins , 2006, Cardiovascular diabetology.

[33]  M. Alevizaki,et al.  Severity of cardiovascular disease in women: relation with exposure to endogenous estrogen. , 2006, Maturitas.

[34]  R. Eckel,et al.  Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. , 2006, Circulation.

[35]  C-C Lin,et al.  Insulin resistance, obesity, and metabolic syndrome among non-diabetic pre- and post-menopausal women in North Taiwan , 2006, International Journal of Obesity.

[36]  S. Tyagi,et al.  Isolated low high density lipoprotein-cholesterol (HDL-C): implications of global risk reduction. Case report and systematic scientific review , 2005, Cardiovascular diabetology.

[37]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[38]  P. Durrington,et al.  The Role of Paraoxonase 1 Activity in Cardiovascular Disease , 2004, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[39]  M. C. Carr,et al.  The emergence of the metabolic syndrome with menopause. , 2003, The Journal of clinical endocrinology and metabolism.

[40]  M. Taskinen.  Diabetic dyslipidaemia: from basic research to clinical practice* , 2003, Diabetologia.

[41]  E. Schaefer,et al.  HDL in atherosclerosis: actor or bystander? , 2003, Atherosclerosis. Supplements.

[42]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[43]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[44]  P. Holvoet,et al.  Oxidized LDL and HDL: antagonists in atherothrombosis , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  E. Schaefer,et al.  Distribution of ApoA-I–Containing HDL Subpopulations in Patients With Coronary Heart Disease , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[46]  A. Baron,et al.  Type II diabetes abrogates sex differences in endothelial function in premenopausal women. , 2000, Circulation.

[47]  E. Poehlman,et al.  Effect of menopausal status on body composition and abdominal fat distribution , 2000, International Journal of Obesity.

[48]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[49]  J. Sowers,et al.  Cardiovascular disease in the diabetic woman. , 1999, The Journal of clinical endocrinology and metabolism.

[50]  C. Conti.  Cardiovascular diabetology. , 1999, Clinical cardiology.

[51]  E. Barrett-Connor,et al.  Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. , 1991, JAMA.

[52]  M. Laakso,et al.  Diabetes and atherosclerosis: an epidemiologic view. , 1987, Diabetes/metabolism reviews.

[53]  A. Dyer,et al.  Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. , 1986, American journal of epidemiology.

[54]  Manning Feinleib,et al.  Obesity as an Independent Risk Factor for Cardiovascular Disease: A 26‐year Follow‐up of Participants in the Framingham Heart Study , 1983, Circulation.

[55]  HELEN B. HUBERT,et al.  Obesity as an Independent Risk Factor for Cardiovascular Disease: A 26‐year Follow‐up of Participants in the Framingham Heart Study , 1983, Circulation.